Rinazal (xylometazoline hydrochloride) nasal spray 1.0 mg/ml. 10 ml. vial

Description

Rinazal (xylometazoline hydrochloride) nasal spray 1.0 mg/ml. 10 ml. vial

Composition 

active ingredient: xylometazoline hydrochloride;

1 ml of solution contains xylometazoline hydrochloride 0.5 mg or 1.0 mg;

excipients: sodium dihydrogen phosphate dihydrate, disodium phosphate dodecahydrate, disodium edetate, benzalkonium chloride, liquid sorbitol, non-crystallizing, hypromelose, sodium chloride, purified water.

Dosage form

Spray nasal, dosed.

Basic physical and chemical properties: colorless transparent liquid.

Pharmacological group

Decongestants and other drugs for topical use in diseases of the nasal cavity. Sympathomimetics, simple drugs. Xylometazoline.
ATX code R01A A07.

Pharmacological properties

These are nasal spray. The active ingredient excites alpha-adrenergic receptors. When applied to the mucous membrane, it causes vasoconstriction, while reducing swelling, redness. With rhinitis (runny nose), relieves nasal breathing.

Indications

Rinazal is used for swelling of the nasal mucosa due to colds, rhinitis with a large amount of liquid mucous secretions (vasomotor rhinitis), as well as allergic rhinitis, acute sinusitis.
In addition, it is indicated for acute otitis media (to restore the patency of the Eustachian tube).

Contraindications

Rinazal nasal spray should not be used:

• with allergies to the components of the solution;
• with “dry” inflammation of the nasal mucosa with the formation of crusts (dry rhinitis);
• with the transferred transsphenoidal removal of the pituitary gland or any other surgical interventions with a history of exposure of the meninges;
• with tachycardia;
• with arterial hypertension;
• during pregnancy, breastfeeding;
• with simultaneous treatment with MAOIs, tricyclic antidepressants;
• children under one year old (drops 0.05%), children up to twelve years old (drops 0.1%).

Use with caution:

• when treating MAOIs or other drugs with a hypertensive effect in the past;
• with increased intraocular pressure, especially with angle-closure glaucoma;
• with cardiovascular pathology (for example, ischemic heart disease, arterial hypertension);
• with pheochromocytoma;
• with metabolic disorders (for example, diabetes mellitus, hyperthyroidism);
• with porphyria;
• with prostatic hyperplasia.

Application during pregnancy and lactation

During these periods, Rinazal is not used.

Method of administration and dosage

The drug is used for adults and children from 12 years old, 1 injection into each nasal passage up to 3 times a day. Apply no more than 3 times in each nasal passage per day.

The duration of treatment depends on the course of the disease and should not exceed 10 consecutive days.

The metered spray ensures dosing accuracy and distribution of the solution over the surface of the nasal mucosa. With each injection, 0.14 ml of the solution is injected, which corresponds to 0.14 mg of xylometazoline.

Before use, it is necessary to bring the dosing device to readiness by performing several injection movements until the spray begins to be released into the air.

With further use, the dosing device will be ready for immediate use.

The spray must be applied as follows:

1. thoroughly clean the nose before using the drug;
2. hold the vial vertically, supporting the bottom with your thumb and placing the tip between two fingers;
3. slightly tilt the bottle and insert the tip into the nasal passage;
4. inject and at the same time take a light breath through the nose;
5. after use, before capping the tip, clean and dry the tip;
6. to prevent infection, each vial of medicine can only be used by one person.

The last application is recommended to be carried out immediately before bedtime.

Children

Rinasal nasal spray dosed at 1 mg/ml should not be used in children under 12 years of age.

Overdose

When applied topically, overdose is unlikely.
Symptoms: mydriasis (dilated pupils), nausea, cyanosis, convulsions, fever, cardiovascular disorders (tachycardia, arterial hypertension, arrhythmia, cardiac arrest), respiratory failure, changes in consciousness, drowsiness, pulmonary edema, decreased body temperature, bradycardia (decrease heart rate), a sharp drop in blood pressure, respiratory arrest, coma development.
Overdose treatment: stopping treatment, seeking medical attention immediately, intensive care.

Side effects:

• Cardiovascular disorders: heart palpitations, arrhythmias, arterial hypertension.
• Neurological disorders: headache, paroxysm, insomnia, fatigue, dizziness.
• Respiratory, thoracic, mediastinal disorders: burning in the nose, feeling of dryness, shortness of breath, sneezing, increased swelling of the nasal mucosa, nosebleeds.
• General disorders: fatigue, drowsiness, visual impairment.
• Digestive disorders: nausea.
• Immune disorders: hypersensitivity reactions (angioedema, exanthema, itching).
• Mental disorders: sleep disturbances, agitation, hallucinations.